MARKET

LRMR

LRMR

Larimar Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.17
-0.42
-4.41%
Opening 15:02 12/06 EST
OPEN
9.56
PREV CLOSE
9.59
HIGH
10.30
LOW
9.13
VOLUME
57.72K
TURNOVER
--
52 WEEK HIGH
25.87
52 WEEK LOW
7.00
MARKET CAP
162.35M
P/E (TTM)
-2.7365
1D
5D
1M
3M
1Y
5Y
Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...
Globe Newswire · 11/22 12:00
In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year.
Insiders who bought Larimar Therapeutics, Inc. ( NASDAQ:LRMR ) in the last 12 months may probably not pay attention to...
Simply Wall St. · 11/20 13:40
Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference
BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...
Globe Newswire · 11/15 12:00
BRIEF-Larimar Therapeutics Reports Q3 Loss Per Share $0.92
reuters.com · 11/12 12:29
Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results
BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter and year to date ...
GlobeNewswire · 11/12 12:00
Mid-Afternoon Market Update: Nasdaq Down 1%; Protagonist Therapeutics Shares Plummet
Toward the end of trading Friday, the Dow traded down 0.47% to 4,587.22 while the NASDAQ fell 1.05% to 15,023.11. The S&P also fell, dropping 0.85% to 4,435.65.
Benzinga · 09/17 19:10
Larimar Therapeutics to Participate in SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines Event
Larimar Therapeutics, Inc. ("Larimar") (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the SVB Leerink C...
GlobeNewswire · 09/16 12:00
Larimar Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
BALA CYNWYD, Pa., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, Presi...
GlobeNewswire · 09/02 20:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LRMR. Analyze the recent business situations of Larimar Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LRMR stock price target is 24.50 with a high estimate of 30.00 and a low estimate of 19.00.
High30.00
Average24.50
Low19.00
Current 9.17
EPS
Actual
Estimate
-0.74-0.55-0.37-0.18
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 87
Institutional Holdings: 14.71M
% Owned: 83.08%
Shares Outstanding: 17.71M
TypeInstitutionsShares
Increased
15
478.86K
New
13
526.80K
Decreased
9
851.79K
Sold Out
4
272.49K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.99%
Pharmaceuticals & Medical Research
-0.70%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Truitt
President/Chief Executive Officer/Director
Carole Ben-Maimon
Chief Financial Officer
Michael Celano
Independent Director
Peter Barrett
Independent Director
Thomas Daniel
Independent Director
Thomas Hamilton
Independent Director
Jonathan Leff
Independent Director
Frank Thomas
No Data
About LRMR
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.

Webull offers kinds of Larimar Therapeutics Inc stock information, including NASDAQ:LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.